Exelixis Inc Income (Loss) from Continuing Operations before Income Taxes, Domestic
Exelixis Inc (EXEL) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $158.58 million for the 12-month period ending 2017-12-29, per its 10-K filed 2018-02-26.
Discontinued › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2018-02-26
- Exelixis Inc income (loss) from continuing operations before income taxes, domestic for fiscal 2017 was $158.58M.
- Exelixis Inc income (loss) from continuing operations before income taxes, domestic for fiscal 2016 was -$70.22M.
- Exelixis Inc income (loss) from continuing operations before income taxes, domestic for fiscal 2016 was -$70.22M.
- Exelixis Inc income (loss) from continuing operations before income taxes, domestic for fiscal 2016 was -$150.85M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2017-12-29 | $158.58M 10-K · filed 2018-02-26 | |
| 2016-12-31 | -$70.22M 10-K · filed 2017-02-27 | |
| 2016-12-30 | -$70.22M 10-K · filed 2018-02-26 | |
| 2016-01-01 | -$150.85M 10-K · filed 2018-02-26 | |
| 2015-12-31 | -$150.85M 10-K · filed 2017-02-27 | -$158.84M 10-K · filed 2016-02-29 |
| 2014-12-31 | -$230.53M 10-K · filed 2017-02-27 | -$237.78M 10-K · filed 2015-03-02 |
| 2013-12-31 | -$236.08M 10-K · filed 2016-02-29 | |
| 2012-12-31 | -$147.54M 10-K · filed 2015-03-02 | |
| 2011-12-31 | $76.99M 10-K · filed 2014-02-20 | |
| 2010-12-31 | -$92.40M 10-K · filed 2012-02-22 | |
| 2009-12-31 | -$140.84M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |